Filing Flows › Aytu Biopharma (AYTU) › Stock forecast & fair value
Aytu Biopharma (AYTU) stock forecast and price target
Aytu Biopharma (AYTU) trades at $1.83. 3 analysts' median price target is $7.00 (+283%), from $7.00 to $15.00.
Aytu Biopharma's latest quarter
Aytu Biopharma, Q4 FY26: revenue $16.1M (+6% year over year), operating margin -4.8%, net loss $15K, operating cash flow $4.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for AYTU stock?
The median of 3 analysts' 12-month targets is $7.00, +283% from $1.83; the range is $7.00 to $15.00. The average rating is none.
Does Aytu Biopharma usually beat earnings estimates?
It beat the consensus EPS estimate in 100% of the quarters on record.
Is AYTU stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.